DE3878991T2 - Peptide boronsaeure-hemmungsstoffe von trypsintyp-proteasen. - Google Patents

Peptide boronsaeure-hemmungsstoffe von trypsintyp-proteasen.

Info

Publication number
DE3878991T2
DE3878991T2 DE8888108817T DE3878991T DE3878991T2 DE 3878991 T2 DE3878991 T2 DE 3878991T2 DE 8888108817 T DE8888108817 T DE 8888108817T DE 3878991 T DE3878991 T DE 3878991T DE 3878991 T2 DE3878991 T2 DE 3878991T2
Authority
DE
Germany
Prior art keywords
boronic acid
acid inhibitors
type proteases
peptide boronic
trypsin type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888108817T
Other languages
English (en)
Other versions
DE3878991D1 (de
Inventor
Charles Adrian Kettner
Ashokkumar Bhikkappa Shenvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of DE3878991D1 publication Critical patent/DE3878991D1/de
Publication of DE3878991T2 publication Critical patent/DE3878991T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8888108817T 1987-06-05 1988-06-01 Peptide boronsaeure-hemmungsstoffe von trypsintyp-proteasen. Expired - Fee Related DE3878991T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5967087A 1987-06-05 1987-06-05
US07/178,368 US5187157A (en) 1987-06-05 1988-04-06 Peptide boronic acid inhibitors of trypsin-like proteases

Publications (2)

Publication Number Publication Date
DE3878991D1 DE3878991D1 (de) 1993-04-15
DE3878991T2 true DE3878991T2 (de) 1993-07-15

Family

ID=26739035

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888108817T Expired - Fee Related DE3878991T2 (de) 1987-06-05 1988-06-01 Peptide boronsaeure-hemmungsstoffe von trypsintyp-proteasen.

Country Status (16)

Country Link
US (1) US5187157A (de)
EP (1) EP0293881B1 (de)
JP (1) JPH0730090B2 (de)
KR (1) KR910003619B1 (de)
AU (1) AU623592B2 (de)
CA (1) CA1328332C (de)
DE (1) DE3878991T2 (de)
DK (1) DK304488A (de)
ES (1) ES2046237T3 (de)
FI (1) FI97297C (de)
HU (1) HU205141B (de)
IE (1) IE64787B1 (de)
IL (1) IL86613A (de)
NO (1) NO882472L (de)
NZ (1) NZ224903A (de)
PT (1) PT87652B (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US6313096B1 (en) 1988-04-28 2001-11-06 Trigen Limited Inhibitors of trypsin-like enzymes
US5574014A (en) * 1988-04-28 1996-11-12 Thrombosis Research Institute Inhibitors of trypsin-like enzymes
NZ229053A (en) * 1988-05-11 1990-12-21 Du Pont Pharmaceutical compositions comprising a protein or peptide and an alpha-aminoboronic acid derivative to stabilise and improve the delivery of the protein or peptide
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
AU2014892A (en) * 1991-04-30 1992-12-21 Procter & Gamble Company, The Liquid detergents with an aryl boronic acid
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
TW232026B (de) * 1991-12-04 1994-10-11 Procter & Gamble
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5576283A (en) * 1992-08-14 1996-11-19 The Procter & Gamble Company Liquid detergents containing a peptide aldehyde
DE69217934T2 (de) * 1992-08-14 1997-09-04 Procter & Gamble Peptidaldehydhaltige flüssige Waschmittel
EP0583536B1 (de) * 1992-08-14 1997-03-05 The Procter & Gamble Company Alpha-aminoborsäurehaltige flüssige Waschmittel
US5442100A (en) * 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5354491A (en) * 1992-08-14 1994-10-11 The Procter & Gamble Company Liquid detergent compositions containing protease and certain β-aminoalkylboronic acids and esters
US5582762A (en) * 1992-08-14 1996-12-10 The Procter & Gamble Company Liquid detergents containing a peptide trifluoromethyl ketone
JPH08504769A (ja) * 1992-12-15 1996-05-21 コルバス・インターナショナル、インコーポレイテッド 因子Ｘａの新規インヒビター
IL108031A0 (en) * 1992-12-22 1994-04-12 Procter & Gamble Difluoro pentapeptide derivatives and pharmaceutical compositions containing them
FR2701951B1 (fr) * 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE153670T1 (de) * 1993-03-03 1997-06-15 Sandoz Ag Peptidboronsäurederivate mit protease inhibierenden aktivität
US5563127A (en) * 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
AU6448794A (en) * 1993-03-24 1994-10-11 Du Pont Merck Pharmaceutical Company, The Boronic acid and ester inhibitors of thrombin
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
AU7922794A (en) * 1993-10-07 1995-05-01 Du Pont Merck Pharmaceutical Company, The Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
GB9401483D0 (en) * 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
ZA951618B (en) * 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
US5436229A (en) * 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
CA2143533A1 (en) * 1994-03-04 1995-09-05 Kenneth D. Kurz Antithrombotic agents
US5488037A (en) * 1994-03-04 1996-01-30 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5484772A (en) * 1994-03-04 1996-01-16 Eli Lilly And Company Antithrombotic agents
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
FR2718448B3 (fr) * 1994-04-12 1996-02-09 Synthelabo Dérivés d'acides aminoboroniques, leur préparation et leur utilisation comme intermédiaires de synthèse.
FR2718451B1 (fr) * 1994-04-12 1996-05-10 Synthelabo Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique.
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
FR2721611B1 (fr) * 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
CN1198839C (zh) * 1995-02-17 2005-04-27 艾伯特有限及两合公司 作为凝血酶抑制剂的新的二肽脒类
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5639739A (en) * 1995-03-24 1997-06-17 The Dupont Merck Pharmaceutical Company Imidazole containing aminoboronic acids
US5731439A (en) * 1995-03-24 1998-03-24 The Dupont Merck Pharmaceutical Company Piperidine containing aminobornic acids
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
DE69637307T2 (de) * 1995-11-28 2008-02-28 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein-und serinproteasehemmer
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
FR2745288B1 (fr) * 1996-02-27 1998-04-17 Adir Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
BR9712114A (pt) 1996-09-24 1999-08-31 Procter & Gamble Composições detergente líquidas para lavanderia contendo enzima proteolítica e inibidores de protease.
US6162783A (en) * 1996-09-24 2000-12-19 The Procter & Gamble Company Liquid detergents containing proteolytic enzyme and protease inhibitors
US6165966A (en) * 1996-09-24 2000-12-26 The Procter & Gamble Company Liquid detergents containing proteolytic enzyme and protease inhibitors
WO1998024886A1 (en) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Mast cell protease that cleaves fibrinogen
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
EE9900584A (et) 1997-06-19 2000-08-15 Dupont Pharmaceuticals Company Neutraalse P1 spetsiifilisusrühmaga faktori Xa inhibiitorid
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
CN1163594C (zh) * 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
ZA988735B (en) * 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
US6011047A (en) * 1997-11-26 2000-01-04 Corvas International Inc. Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors
US6204384B1 (en) 1997-11-26 2001-03-20 Corvas International, Inc. Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (II)
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
BR9907112A (pt) 1998-01-26 2000-10-24 Basf Ag Composto, medicamento, e, uso de um composto
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
CA2331122A1 (en) * 1998-05-04 1999-11-11 Point Therapeutics, Inc. Hematopoietic stimulation
EP1084129B1 (de) 1998-06-05 2003-01-22 Point Therapeutics, Inc. Cyclische boroprolinverbindungen
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
ES2295004T3 (es) 1999-01-13 2008-04-16 Astrazeneca Ab Nuevos derivados amidinobencilaminicos y su uso como inhibidores de trombina.
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
FI2251344T4 (fi) * 2001-01-25 2024-04-29 The United States Of America Represented By The Secretary Boronihappoyhdisteiden formulointi
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6777431B2 (en) 2001-07-13 2004-08-17 Corvas International, Inc. Non-convalent thrombin inhibitors
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
IL166157A0 (en) * 2002-07-09 2006-01-15 Point Therapeutics Inc Methods and compositions relating to isoleucine boroproline compounds
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
ES2457593T3 (es) 2004-03-30 2014-04-28 Millennium Pharmaceuticals, Inc. Síntesis de bortezomib
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
PT2178888E (pt) 2007-08-06 2012-10-04 Millennium Pharm Inc Inibidores do proteassoma
ES2575131T3 (es) * 2007-12-03 2016-06-24 Obe Therapy Biotechnology Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa
US9212155B2 (en) 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
JP5746612B2 (ja) 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
GB0807828D0 (en) * 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
EA201500431A1 (ru) 2008-06-17 2015-11-30 Милленниум Фармасьютикалз, Инк. Соединения боронатного эфира и его фармацевтические составы
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2344165A4 (de) * 2008-10-01 2012-12-05 Reddys Lab Ltd Dr Pharmazeutische zusammensetzungen mit boronsäureverbindungen
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
JP5783659B2 (ja) 2009-12-22 2015-09-24 セファロン、インク． プロテアソーム阻害剤およびその調製、精製および使用のための方法
NZ602622A (en) 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8962572B2 (en) 2010-10-05 2015-02-24 Fresenius Kabi Usa, Llc Bortezomib formulations
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013128419A2 (en) 2012-03-02 2013-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
PH12015501492A1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
CA2909519A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
SI3305778T1 (sl) 2013-05-23 2022-04-29 Kalvista Pharmaceuticals Limited Zaviralci plazemskega kalikreina
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
PL3033336T3 (pl) 2013-08-14 2018-11-30 Kalvista Pharmaceuticals Limited Inhibitory kalikreiny w plaźmie
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
EP3102585B1 (de) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronsäureester und pharmazeutische formulierungen daraus
US20150335668A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals, Inc. Method for cancer therapy
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
WO2016146516A1 (en) 2015-03-17 2016-09-22 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
HUE049918T2 (hu) 2016-05-31 2020-11-30 Kalvista Pharmaceuticals Ltd Pirazol-származékok mint plazma kallikrein inhibitorok
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B1 (en) 2017-11-29 2024-05-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
WO2022079446A1 (en) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318904A (en) * 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
JPS61112018A (ja) * 1984-11-06 1986-05-30 Mitsubishi Chem Ind Ltd 線溶増強剤
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity

Also Published As

Publication number Publication date
EP0293881A2 (de) 1988-12-07
IL86613A (en) 1993-04-04
JPS6463583A (en) 1989-03-09
EP0293881A3 (en) 1990-05-30
AU623592B2 (en) 1992-05-21
DK304488A (da) 1988-12-06
FI97297C (fi) 1996-11-25
IE64787B1 (en) 1995-09-06
ES2046237T3 (es) 1994-02-01
NO882472D0 (no) 1988-06-03
JPH0730090B2 (ja) 1995-04-05
HUT49629A (en) 1989-10-30
DK304488D0 (da) 1988-06-03
EP0293881B1 (de) 1993-03-10
HU205141B (en) 1992-03-30
FI97297B (fi) 1996-08-15
IE881666L (en) 1988-12-05
FI882638A (fi) 1988-12-06
KR890000514A (ko) 1989-03-15
AU1733288A (en) 1988-12-08
NO882472L (no) 1988-12-06
CA1328332C (en) 1994-04-05
KR910003619B1 (ko) 1991-06-07
FI882638A0 (fi) 1988-06-03
DE3878991D1 (de) 1993-04-15
IL86613A0 (en) 1988-11-30
PT87652A (pt) 1988-07-01
PT87652B (pt) 1992-09-30
NZ224903A (en) 1990-02-26
US5187157A (en) 1993-02-16

Similar Documents

Publication Publication Date Title
DE3878991T2 (de) Peptide boronsaeure-hemmungsstoffe von trypsintyp-proteasen.
DK674387D0 (da) Proteaseinhibitorer
DE3689314D1 (de) Peptidasehemmungsmittel.
DE3785615D1 (de) Hemmungsstoffe der serin-protease.
NO863581L (no) Hydroksamsyrebaserte kollagenaseinhibitorer.
DE68906894T2 (de) Erfassung von verbrauchswerten.
ATE71111T1 (de) Peptid-derivate, renin- und saeureprotease hemmende mittel.
DE3685626D1 (de) Sequenzierung von peptiden.
DE3869007D1 (de) Oxydation von alkanen.
DE69326077T2 (de) Sulfonylalkanoylaminohydroxyethylaminosulfaminsäuren verwendbar als inhibitoren retroviraler proteasen
NO882226D0 (no) Fibrinolytiske proteiner.
DE68912685D1 (de) Reinigung von Glucosaminoglucan abbauenden Enzymen.
FI935644A (fi) Retrovirusten proteaasi-inhibiittoreita
NO895026D0 (no) Retrovirale proteasehemmere.
DE3883439D1 (de) Bestimmung von Peptidsequenzen.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
ATE49214T1 (de) Platinkomplexe von aliphatischen tricarbonsaeuren.
DK429585D0 (da) Antibakterielt virksomme 4,5-dihydro-4-oxo-2-((2-trans-phenylcyclopropyl)amino)-3-furancarboxylsyrer og derivater deraf
DE3576527D1 (de) Trennung von aminosaeureracematen.
DE3765784D1 (de) Zusammensetzung von aminosaeuren.
ATE86628T1 (de) Peptide boronsaeure-hemmungsstoffe von trypsintyp- proteasen.
NO881502L (no) Rekombinante htlv-111-proteiner og anvendelser av disse.
DE69010271T2 (de) Regenerierung von verbrauchten Ferrichlorid-Ätzmitteln.
ZA883953B (en) Peptide boronic acid inhibitors of trypsin-like proteases
DK658489A (da) Proteaseinhibitorer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DU PONT PHARMACEUTICALS CO., WILMINGTON, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: BRISTOL-MYERS SQUIBB PHARMA CO., PRINCETON, N.J.,

8339 Ceased/non-payment of the annual fee